NASDAQ:BLUE - bluebird bio Stock Price, Forecast & News

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

bluebird bio Inc (NASDAQ:BLUE) released its quarterly earnings results on Thursday, October, 31st. The biotechnology company reported ($3.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($3.54) by $0.19. The biotechnology company earned $8.91 million during the quarter, compared to analyst estimates of $12.47 million. bluebird bio had a negative return on equity of 42.29% and a negative net margin of 1,326.56%. The business's revenue was down 22.7% compared to the same quarter last year. During the same period last year, the firm earned ($2.73) earnings per share. View bluebird bio's Earnings History.

bluebird bio is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for bluebird bio.

18 equities research analysts have issued 1-year price objectives for bluebird bio's shares. Their forecasts range from $96.00 to $195.00. On average, they anticipate bluebird bio's stock price to reach $134.99 in the next year. This suggests a possible upside of 37.7% from the stock's current price. View Analyst Price Targets for bluebird bio.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 6 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for bluebird bio.

Press coverage about BLUE stock has been trending positive recently, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. bluebird bio earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for bluebird bio.

bluebird bio saw a increase in short interest in December. As of December 13th, there was short interest totalling 8,610,000 shares, an increase of 5.9% from the November 28th total of 8,130,000 shares. Based on an average daily volume of 1,210,000 shares, the days-to-cover ratio is presently 7.1 days. Approximately 15.7% of the company's shares are sold short. View bluebird bio's Current Options Chain.

Some companies that are related to bluebird bio include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP) and Allogene Therapeutics (ALLO).

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include Opko Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Celgene (CELG), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU) and ABIOMED (ABMD).

bluebird bio's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.24%), Rhenman & Partners Asset Management AB (0.10%) and Ingalls & Snyder LLC (0.02%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, James Mandell, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio.

BLUE stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, David Davidson, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Nick Leschly and Philip D Gregory. View Insider Buying and Selling for bluebird bio.

BLUE stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Rhenman & Partners Asset Management AB. View Insider Buying and Selling for bluebird bio.

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BLUE stock can currently be purchased for approximately $98.04.

bluebird bio has a market capitalization of $5.42 billion and generates $54.58 million in revenue each year. The biotechnology company earns $-555,630,000.00 in net income (profit) each year or ($10.68) on an earnings per share basis. bluebird bio employs 764 workers across the globe.View Additional Information About bluebird bio.

The official website for bluebird bio is http://www.bluebirdbio.com/.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]